RxDoctor Payments Data

Regina Stein, MD

Hematology & Oncology · Chicago, ILNPI 1245241983

Payments from drug & device makers

$169,672in general payments, 2019–2025

Across 18 payments — averaging $9426.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$120K
  • Pfizer$49K
  • Gilead$275
  • Merck$96
  • Johnson & Johnson$34
  • Amgen$34

What the payments were for

  • Food & beverage$43474%
  • Education$15426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$120,079
Pfizer8$49,153
Gilead4$275
Merck1$96
Johnson & Johnson1$34
Amgen1$34

How this compares

$169,672 in reported general payments places this provider in the 75th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,247,201
Medicare patients
727
Services billed
96,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib20$306,651
EliquisApixaban248$202,467
PromactaEltrombopag Olamine14$121,039
XareltoRivaroxaban45$49,606
Exemestane46$10,102
Letrozole232$5,234
Anastrozole100$2,394
Enoxaparin Sodium15$2,334
Hydroxyurea20$376
Tamoxifen Citrate19$306
Warfarin Sodium32$296
Pantoprazole Sodium27$179
Gabapentin26$138
Prednisone12$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$49,153$509,118268 claims
Johnson & JohnsonXarelto$34$49,60645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →